Taxotere Sales Force Restructured To Bolster Growth, Fend Off Competition
Executive Summary
Sanofi-Aventis has reorganized its U.S. Taxotere sales force to drive growth of the oncologic amid an increasingly competitive environment, the firm said
You may also be interested in...
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011